How to access Cyltezo (Humira biosimilar) from Abu Dhabi: 2026 pathway via SSMC, CCAD, Tawam, SKMC, and Burjeel Medical City | Reserve Meds

*Clinically reviewed by Reserve Meds AI Clinical and Regulatory Review (see /trust). Last reviewed 2026-05-20.

Abu Dhabi treats large adalimumab populations across rheumatology, dermatology, gastroenterology, ophthalmology, and paediatric specialty at SSMC, CCAD, Tawam, SKMC, and Burjeel Medical City. The 2026 question for Humira patients is whether to switch to Cyltezo, the FDA interchangeable biosimilar.

Why Cyltezo, why now

Cyltezo (adalimumab-adbm) is a Boehringer Ingelheim biosimilar of the reference biologic Humira (adalimumab). The US FDA approved Cyltezo in August 2017 and granted interchangeability designation in October 2021, making it the first interchangeable adalimumab biosimilar in the United States. Cyltezo carries the same indications as reference Humira: rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis aged 4 and older, ankylosing spondylitis (AS), psoriatic arthritis (PsA), moderate-to-severe plaque psoriasis (adults and paediatric aged 6 and older), Crohn's disease (adults and paediatric aged 6 and older), ulcerative colitis (adults and paediatric aged 5 and older), hidradenitis suppurativa (adults and paediatric aged 12 and older), and non-infectious uveitis. Standard dosing is 40 mg subcutaneously every other week after loading, varying by indication and patient weight.

The 2026 question for an Abu Dhabi patient on Humira is whether to switch to Cyltezo to reduce annual drug cost while retaining the same molecular activity. Abu Dhabi has the UAE's strongest in-emirate specialty depth across rheumatology, dermatology, gastroenterology, and ophthalmology at Sheikh Shakhbout Medical City (SSMC), Cleveland Clinic Abu Dhabi (CCAD), Tawam Hospital, Sheikh Khalifa Medical City (SKMC), and Burjeel Medical City. Reserve Meds does not promote one TNF biosimilar over another or over the reference biologic. Other US-approved Humira biosimilars include Amjevita, Hyrimoz, Hadlima, Yusimry, Abrilada, Hulio, Idacio, Yuflyma, and others.

What Cyltezo is, in plain language

Cyltezo is a subcutaneous adalimumab biosimilar supplied as a prefilled pen or prefilled syringe. After clinic-supervised training, the patient self-administers at home every other week. Onset of clinical effect is gradual, typically with partial response by week 4 and fuller response by week 12 to 24 depending on indication. Cyltezo is interchangeable with Humira per FDA designation, meaning the molecular activity is clinically equivalent.

Access pathway in Abu Dhabi

The Emirates Drug Establishment (EDE), formed in 2024 by consolidating the federal medicine regulatory mandate previously held by the Ministry of Health and Prevention (MOHAP), oversees federal-level medicine registration, import licensing, and pharmacovigilance. The Department of Health Abu Dhabi (DoH Abu Dhabi) governs healthcare facility licensing in the emirate. Cyltezo's EDE registration status is variable; where Cyltezo is not yet registered, access runs through an EDE-approved named-patient personal-import authorisation, with DoH Abu Dhabi acknowledgment, filed by the treating specialist at SSMC, CCAD, Tawam, SKMC, or Burjeel Medical City.

The treating physician submits a named-patient import application documenting the indication, prior treatment history, hepatitis B and TB screening results, and the requested dose and shipment quantity. EDE reviews and issues an import authorisation per shipment. Reserve Meds sources Cyltezo from a US DSCSA-compliant specialty wholesaler, prepares the manufacturer pedigree, and ships under validated cold chain to Abu Dhabi International Airport.

Eligibility at an Abu Dhabi specialty clinic

The treating specialist confirms the indication, screens for chronic hepatitis B (HBsAg, anti-HBc, HBV DNA if reactive), latent TB (IGRA or Mantoux plus chest radiograph), and active infection. Vaccination status is reviewed and any live vaccines updated before initiation. Pregnancy plans are documented for women of childbearing potential. Heart failure status is assessed (NYHA Class III or IV is a contraindication). Paediatric cases are typically managed at Tawam, CCAD, or SSMC.

Documentation required

The patient and physician should be prepared to provide: a current Emirates ID or passport; the specialist's diagnostic file confirming the indication; documentation of prior therapy and response, where applicable; recent hepatitis B serology and TB screening results; recent complete blood count, liver function, renal function; the treating physician's prescription on hospital letterhead; the clinical justification letter; the EDE named-patient import application; the DoH Abu Dhabi acknowledgment; and evidence of payment capacity or insurance pre-authorisation. Reserve Meds prepares the US export documentation, manufacturer pedigree, and customs packet.

Costs and funding considerations

The annual cost band for Cyltezo in Abu Dhabi is USD 40,000 to 60,000 per patient (AED 150,000 to 220,000), materially lower than the reference Humira band. Thiqa for Emirati nationals covers under chronic-disease formulary once eligibility is confirmed. Daman Enhanced, Daman Premier, AXA Gulf, Allianz, MetLife, and BUPA Arabia plans active in Abu Dhabi increasingly favour adalimumab biosimilars on UM grounds, generally covering with pre-authorisation. Reserve Meds will help structure the insurer or Thiqa submission.

Typical timeline

Weeks 0 to 2: confirm indication, complete hepatitis B and TB screening, prescription preparation, EDE filing. Weeks 2 to 4: shipment arrival at Abu Dhabi International Airport, clinic-supervised injection one to two sessions, patient or caregiver training. Weeks 4 to 12: every-other-week SC at home; partial response by week 4, fuller response by week 12 depending on indication. Months 6 and 12: full reassessment using indication-specific disease activity scores.

When Cyltezo is the wrong drug

Active untreated tuberculosis or hepatitis B reactivation risk must be treated first; TNF inhibition is contraindicated until that is addressed. NYHA Class III or IV heart failure is a contraindication. Demyelinating disease is a relative contraindication. Active malignancy other than non-melanoma skin cancer is a contraindication. Patients with documented non-response to adalimumab or with neutralising anti-drug antibodies should be considered for an alternative TNF or a different mechanism class rather than another adalimumab biosimilar. Reserve Meds does not promote one TNF biosimilar over another or over the reference biologic.

Frequently asked questions

• Is the pathway legal in Abu Dhabi? Yes. It operates under EDE named-patient personal-import authorisation with DoH Abu Dhabi acknowledgment under federal UAE medicines law.
• Will Thiqa or my insurance cover Cyltezo? Emirati nationals may secure Thiqa chronic-disease coverage; private insurance pre-authorisation is generally available where indication is documented.
• Is the molecular activity the same as Humira? Yes; FDA interchangeability designation confirms clinical equivalence with the reference biologic.
• How is Cyltezo shipped? Validated cold chain (2 to 8 degrees Celsius) with temperature-monitored containers from a US DSCSA-compliant specialty wholesaler to Abu Dhabi International Airport.
• Can my child use Cyltezo? Cyltezo is FDA-approved for paediatric patients across multiple indications. Paediatric cases in Abu Dhabi are typically managed at Tawam, CCAD, or SSMC.
• What if Cyltezo is in short supply? Reserve Meds will inform you upfront and decline rather than promise a timeline we cannot deliver. We do not source from unverified channels.

Closing

Reserve Meds runs the Cyltezo supply file from the SSMC, CCAD, Tawam, SKMC, or Burjeel specialty referral through EDE registration or named-patient pathway and delivered cold-chain supply. Clinical decisions remain with your treating specialist. To open a case, start your file in the patient portal or message us on WhatsApp; we will return a delivered quote within 24 hours.

---

Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating specialist. Reserve Meds does not promote one TNF biosimilar over another or over the reference biologic.

Clinical and regulatory review: Reserve Meds AI Clinical and Regulatory Review (see /trust). Last medically reviewed: 2026-05-20.